Mirtazapine Indications
Mirtazapine is FDA-approved for the treatment of major depressive disorder (MDD) in adults 1.
Primary Indication
The FDA drug label clearly states that mirtazapine tablets are indicated specifically for major depressive disorder (MDD) in adults 1. This represents the only formal regulatory approval for this medication.
Clinical Context from Guidelines
The American College of Physicians (ACP) guidelines position mirtazapine within the broader category of second-generation antidepressants for treating depressive disorders 2. Key points include:
- Mirtazapine demonstrates a statistically significantly faster onset of action compared to SSRIs (citalopram, fluoxetine, paroxetine, or sertraline), though response rates become similar after 4 weeks 2
- It shows equivalent efficacy to other second-generation antidepressants for acute-phase MDD treatment 2
- The ACP recommends selecting second-generation antidepressants (including mirtazapine) based on adverse effect profiles, cost, and patient preferences rather than efficacy differences 2
Off-Label Uses Supported by Evidence
While not FDA-approved for these conditions, research suggests potential efficacy in:
- Anxiety disorders (including post-traumatic stress disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder) 3, 4, 5
- Obsessive-compulsive disorder 4, 5
- Adjunctive treatment in schizophrenia (for negative and cognitive symptoms) 6, 4
- Irritable bowel syndrome (particularly IBS-D) 7
However, these applications require further large-scale randomized controlled trials for definitive recommendations 4.
Important Clinical Considerations
Common adverse effects include somnolence, weight gain, and increased appetite due to antihistaminic (H1) activity, particularly at lower doses 2, 8. The sedative properties may be advantageous when treating depression with comorbid insomnia or anxiety 3, 8.
Mirtazapine should be used with caution in patients with cardiovascular disease, seizure disorders, or hepatic impairment 1. Screen patients for bipolar disorder history before initiating treatment, as activation of mania/hypomania occurred in 0.2% of treated patients 1.